New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

Semaglutide May Increase Nonarteritic Anterior Ischemic Optic Neuropathy Risk

Study draws correlative connection between semaglutide and nonarteritic anterior ischemic optic neuropathy, more data required to show causation.

ACC 25: semaglutide reduces total cardiovascular events in latest SELECT results

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow.The post ACC 25: semaglutide reduces total cardiovascular events in latest SELECT results appeared first on Clinical Trials Arena.

News of the Day and the Hour Latest News of today In the framework of Diabetes Alert Day, Dr. Alamí Rivero Franco, a surgeon and expert in regenerative medicine, presented advances in the treatment of diabetes mellitus through stem cell therapies, which have shown promising results in improving the quality of life of patients. Diabetes, one of the most common diseases today, affects millions of people in the world. Dr. Rivero highlighted the im…

GLP-1 Receptor Agonists Offer Less Invasive Alternative to Bariatric Surgery for CV Health in Obese Patients

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

March 2025 Medical Article About Blindness or Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients

Discusses Timing for Increased Risk of Semaglutide-related Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Side Effect   (Posted by Tom Lamb at Drug Injury Watch)   On March 27, 2025, the JAMA Ophthalmology medical journal published a report about a recent medical study examining the relatively new drug safety issue of vision loss and blindness due to NAION linked to Ozempic and Rybelsus use by patients with type 2 diabetes. As stated in…